Information Provided By:
Fly News Breaks for July 31, 2018
TNDM
Jul 31, 2018 | 08:55 EDT
Lake Street analyst Brooks O'Neil raised his price target for Tandem Diabetes to $35 saying the company's momentum continued during Q2. Revenue growth accelerated from 43.7% in Q1 to 60.0% in the quarter and the operating margin improved, O'Neil tells investors in a post-earnings research note. He affirms a Buy rating on the shares.
News For TNDM From the Last 2 Days
TNDM
TNDM
Apr 25, 2024 | 06:02 EDT
Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.